Join the 'Ocu-Trol' group to help and get support from people like you.
Posted 6 Oct 2016 by Drugs.com
THURSDAY, Oct. 6, 2016 – Adding a newer drug to a standard treatment for advanced cases of multiple myeloma may significantly boost patients' chances of a response and even recovery, a new clinical trial finds. Of patients given the drug, called daratumumab, 43 percent had a complete response – meaning there were no signs of the cancer left. That compared with 19 percent of patients who received a standard drug duo alone. And over 13.5 months, the daratumumab combination cut patients' risk of dying or seeing their cancer progress by 63 percent, the study found. Researchers called the results "unprecedented" for patients like these. All had relapsed or refractory myeloma – which means the cancer had either come back or failed to respond to the previous treatment. "It is very likely that (this regimen) will be rapidly adopted by practicing physicians," said lead researcher Dr. Meletios ... Read more
Related support groups: Dexamethasone, Multiple Myeloma, Revlimid, Decadron, TobraDex, Ciprodex, Maxitrol, Ozurdex, Osteolytic Bone Lesions of Multiple Myeloma, Tobradex ST, Dexamethasone/Neomycin/Polymyxin B, Lenalidomide, Decadron Tablets, Dexamethasone/Tobramycin, Adrenocot, Maxidex, Dexone, Poly-Dex, Decadron Dose Pack, Dexpak Taperpak